Granted in-principle approval for the merger of KIA Health Tech Private Limited, wholly owned subsidiary of the Company, with Rubicon Research Limited and their shareholders Further to the in-principle approval granted on February 3, 2026, the Board of Directors of both respective companies have placed and approved the Scheme of Merger for Kia Health Tech Private Limited, a wholly owned subsidiary, (Transferor Company) with the Company, under Section 233 of the Companies Act, 2013 read with Rule 25 of the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016. The Appointed Date under the Scheme is April 1, 2026. Since the Transferor Company is a wholly owned subsidiary of the Company, no shares of the Company will be issued, and no consideration will be payable pursuant to the Scheme. Consequently, there will be no change in the shareholding pattern or voting rights of the Company. (As Per BSE Announcement Dated on:20.07.2026). Filing of Scheme of Merger of KIA Health Tech Pvt Ltd (WOS) with Rubicon Research Limited - for Disclosure Purposes Only, in terms of the Exemption under Para 4 of SEBI Master circular No. SEBI/HO/CFD/POD-2/p/CIR/2023/93 dated June 20, 2023. (As per BSE announcement dated on : 22.07.2026)